Nephros Q1 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.522M Miss $3.734M Estimate
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.03) per sha
The Analyst Landscape: 7 Takes On Azenta
Across the recent three months, 7 analysts have shared their insights on Azenta (NASDAQ:AZTA), expressing a variety of opinions spanning from bullish to bearish.The following table encapsulates their
BioLife Solutions Reiterates Guidance
2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based on expectations for BioLife's Cell Processing and Biostorage Services pl
Bionano Stock Climbs 7% in Wake of Q1 Report, Software Upgrades
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results.Duolingo reported quarterly earnings of 57 cents per share whic
Femasys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 915.15% HC Wainwright & Co. → $13 Reiterates Buy → Buy 04/01/2024 837.06% Chardan Capital $12 →